|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
D’Addario G and Felip E; ESMO Guidelines
Working Group. Non-small-cell lung cancer: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20(Suppl 4): 68–70. 2009.
|
|
3
|
Gkiozos I, Charpidou A and Syrigos K:
Developments in the treatment of non-small cell lung cancer.
Anticancer Res. 27:2823–2827. 2007.PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katayama M, Kawaguchi T, Berger MS and
Pieper RO: DNA damaging agent-induced autophagy produces a
cytoprotective adenosine triphosphate surge in malignant glioma
cells. Cell Death Differ. 14:548–558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levine B and Yuan J: Autophagy in cell
death: an innocent convict? J Clin Invest. 115:2679–2688. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ravikumar B, Sarkar S, Davies JE, et al:
Regulation of mammalian autophagy in physiology and
pathophysiology. Physiol Rev. 90:1383–1435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gozuacik D and Kimchi A: Autophagy as a
cell death and tumor suppressor mechanism. Oncogene. 23:2891–2906.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rollins KD and Lindley C: Pemetrexed: a
multitargeted antifolate. Clin Ther. 27:1343–1382. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramirez JM, Ocio EM, San Miguel JF and
Pandiella A: Pemetrexed acts as an antimyeloma agent by provoking
cell cycle blockade and apoptosis. Leukemia. 21:797–804.
2007.PubMed/NCBI
|
|
11
|
Yang TY, Chang GC, Chen KC, et al:
Pemetrexed induces both intrinsic and extrinsic apoptosis through
ataxia telangiectasia mutated/p53-dependent and -independent
signaling pathways. Mol Carcinog. 52:183–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tonkinson JL, Worzalla JF, Teng CH and
Mendelsohn LG: Cell cycle modulation by a multitargeted antifolate,
LY231514, increases the cytotoxicity and antitumor activity of
gemcitabine in HT29 colon carcinoma. Cancer Res. 59:3671–3676.
1999.PubMed/NCBI
|
|
13
|
McLeod HL, Cassidy J, Powrie RH, et al:
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide
ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res.
6:2677–2684. 2000.PubMed/NCBI
|
|
14
|
Shih C, Chen VJ, Gossett LS, et al:
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits
multiple folate-requiring enzymes. Cancer Res. 57:1116–1123.
1997.
|
|
15
|
D’Angelo SP, Kris MG, Pietanza MC, Rizvi
NA and Azzoli CG: A case series of dose-limiting peripheral edema
observed in patients treated with pemetrexed. J Thorac Oncol.
6:624–626. 2011.PubMed/NCBI
|
|
16
|
Mujumdar N, Mackenzie TN, Dudeja V, et al:
Triptolide induces cell death in pancreatic cancer cells by
apoptotic and autophagic pathways. Gastroenterology. 139:598–608.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ciuleanu T, Brodowicz T, Zielinski C, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: a
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bareford MD, Hamed HA, Tang Y, et al:
Sorafenib enhances pemetrexed cytotoxicity through an
autophagy-dependent mechanism in cancer cells. Autophagy.
7:1261–1262. 2011. View Article : Google Scholar
|
|
21
|
Nakai A, Yamaguchi O, Takeda T, et al: The
role of autophagy in cardiomyocytes in the basal state and in
response to hemodynamic stress. Nat Med. 13:619–624. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baehrecke EH: Autophagy: dual roles in
life and death? Nat Rev Mol Cell Biol. 6:505–510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Debnath J, Baehrecke EH and Kroemer G:
Does autophagy contribute to cell death? Autophagy. 1:66–74. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng X, Overmeyer JH and Maltese WA:
Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase
complex in macroautophagy versus endocytosis and lysosomal enzyme
trafficking. J Cell Sci. 119:259–270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pattingre S, Espert L, Biard-Piechaczyk M
and Codogno P: Regulation of macroautophagy by mTOR and Beclin 1
complexes. Biochimie. 90:313–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanematsu S, Uehara N, Miki H, et al:
Autophagy inhibition enhances sulforaphane-induced apoptosis in
human breast cancer cells. Anticancer Res. 30:3381–3390.
2010.PubMed/NCBI
|
|
28
|
Liu D, Yang Y, Liu Q and Wang J:
Inhibition of autophagy by 3-MA potentiates cisplatin-induced
apoptosis in esophageal squamous cell carcinoma cells. Med Oncol.
28:105–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
